Metabolon strikes research, licensing deals for diabetes tech

02/25/2014 | GenomeWeb Daily News (free registration)

Metabolon has agreed to allow Patia Biopharma to exclusively license its prediabetes test for insulin resistance assessment in Mexico. The company also struck research deals for its Quantose IR system to be used in large-scale Mexican trials aimed at earlier detection of prediabetes to prevent its progression to type 2 diabetes. Terms of the deals were not made public.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN